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Abstract
National and international public–private partnerships,
consortia, and government initiatives are underway to
collect and share genomic, personal, and healthcare
data on a massive scale. Ideally, these efforts will
contribute to the creation of a medical information
commons (MIC), a comprehensive data resource that
is widely available for both research and clinical uses.
Stakeholder participation is essential in clarifying goals,
deepening understanding of areas of complexity, and
addressing long-standing policy concerns such as
privacy and security and data ownership. This article
describes eight core principles proposed by a diverse
group of expert stakeholders to guide the formation
of a successful, sustainable MIC. These principles
promote formation of an ethically sound, inclusive,
participant-centric MIC and provide a framework for
advancing the policy response to data-sharing
opportunities and challenges.
Background
In 2011, a National Academies report advocated for the
creation of an “Information Commons,” an individual-
centric, multilayered, widely accessible informational
resource to support integration and use of data from
biomedical research and clinical care for precision medi-
cine [1]. This report built on the spirit of open science
embodied in the publicly funded Human Genome Project
and its Bermuda Principles, which were modeled on data-
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sharing practices in nematode biology and called for daily
sharing of DNA sequence data well before publication
[2]. Since then, data initiatives facilitating clinical and
genomic data sharing have proliferated across multiple
sectors and internationally. The term “commons” in
this context evokes the groundbreaking work of Nobel
laureate Elinor Ostrom, who developed a theoretical
framework to address governance challenges in build-
ing and sustaining shared natural resources [3]. She
and others then extended the concept to “knowledge
commons,” applying to resources that are not necessar-
ily depleted by use [4]. This framework has informed
sophisticated commentary on the challenges of data
sharing in the healthcare context [5].
One lesson from Ostrom’s work is that a successful,
sustainable commons requires stakeholder participation.
With health data, stakeholder engagement is required to
address long-standing policy concerns about data access,
privacy and security protections, data ownership, and
issues of data quality, interoperability, and network sus-
tainability. Without a nuanced understanding of these
complexities and a policy framework to address them, it
will be difficult to obtain stakeholder buy-in and to
realize the promise of advancing precision medicine and
promoting a learning healthcare system.
In an effort to enact Ostrom’s lessons and to begin to
address these critical issues, we have joined together as rep-
resentatives of a range of stakeholders, including healthcare
systems, clinical laboratories, technology companies, aca-
demia, government, nongovernmental organizations, and
patient and community advocacy groups. Drawing on our
first-hand experiences, we have created an initial list of
eight core principles (1–8) for building a successful, sus-
tainable medical information commons (MIC), defined as
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“a networked environment in which diverse health, medical,
and genomic data on large populations become broadly
available for research use and clinical applications”.
Core principles
1. The MIC should be a healthy “ecosystem” of data
initiatives connected through a standard approach to
policy, interoperability, and collaborative work
The MIC does not refer to a particular network archi-
tecture, but rather to an ecosystem that encompasses
multiple actors and a comprehensive, high-level,
stakeholder-informed framework to guide decision mak-
ing about data control and access. Some of the initiatives
contributing to the MIC may have their own policies and
governance structures for sharing data. Thus, the larger
MIC may encompass multiple smaller commons, as de-
fined by Elinor Ostrom. Rather than attempting to create
uniformity, the preferred approach is to develop core prin-
ciples (including the eight set forth here) and policies that
ensure the needs and concerns of key stakeholders are
considered and addressed across different models.
Building the MIC ecosystem will require not only the
creation of appropriate stakeholder-specific incentives
for sharing data, but also new approaches in how large-
scale data-sharing policies are developed and implemented
by academia, industry, and government. The Global Alli-
ance for Genomics and Health and the Patient-Centered
Outcomes Research Network are current examples of
experiments in multistakeholder policy development.
2. The MIC must bring together diverse sources of data
from individuals with different states of health
An optimal MIC would include diverse sources of data
from a broad range of individuals. Data (phenome and
demographics) would be obtained from electronic health
records, genomes, and personal health and environmen-
tal sources, including wearables, and would be voluntar-
ily shared by individuals and continuously updated
throughout their lives. Including data from a broad
range of individuals is essential to enable analysis of dis-
ease risk, identification of factors contributing to disease
resistance/resilience, and testing of pharmacogenomic
targets. Aggregation could be accomplished through
multiple strategies, including: linking data from current
or planned large-scale population-based initiatives (like
the Precision Medicine Initiative’s All of Us Research
Program) and research efforts by health systems (such as
Kaiser-Permanente and Partners HealthCare); linking
disease-specific repositories; directing data from existing
cohorts into a centralized data repository; and compiling
searchable metadata into a directory or index that en-
ables authorized inquiries to be directed to the location
where responsive data are held.
Furthermore, targeting recruitment of individuals in
various states of health would provide a rich data source.
Researchers and clinicians would have access to informa-
tion to understand the full spectrum of disease etiologies
and define the natural history of disease, accelerate the de-
velopment of more accurate diagnoses and treatments,
and reduce the difficulty, time, and expense of identifying
and recruiting relevant cohorts for clinical studies. How-
ever, interoperability and adopting data-sharing policies
that maximize the utility of the data across heterogeneous
sources are major challenges for the MIC. The variation
between the many electronic health record formats cre-
ated by different companies, customized for different
health systems, and tailored for different purposes from
medical value to ease of billing, magnify these challenges.
3. A participant-centric model is critical for the sustain-
ability of the MIC
The existing opaque system of exchanging data built solely
around data holders and users must transition to a system
that involves participants. Involvement may require that
the system is built with the participant at the center, or at
least require a system that more meaningfully empowers
the individuals whose data are being shared to make deci-
sions about access and use [6, 7]. Empowerment requires
not just giving participants choices but helping them
understand their choices in a very technical area. Policy
development should focus on options that simplify the
system as much as possible, including the possibility of
inserting trusted intermediaries to navigate the complex
politics involved in data exchange [8]. Tools such as
Blockchain, FHIR, Sync for Science and Sync for Genes,
Private Access, and Blue Button can be refined and/or cre-
ated to facilitate the ability of individuals to contribute
and control data in the MIC. Use of these tools promotes
autonomous and informed decision making without
requiring that individuals own their data in a legal sense
or exercise exclusive unstructured control over access to
their data (see principle 8).
If data-sharing initiatives subscribing to the participant-
centric model are to thrive within the MIC, strategies
supporting an individual’s choice to contribute data dir-
ectly to the MIC must be developed. These strategies
should be simple, convenient, dynamic, community-based,
and grounded in an ethical foundation that builds and
sustains trust by being trustworthy. Existing US law gener-
ally gives individuals the right to access their healthcare
data and requires covered entities to share it with others
(including in electronic form), but more work is needed to
help individuals exercise this right and to implement au-
thorized data access and transfer [6, 7]. As the MIC
evolves, community-driven and community-based efforts
will likely increase in number, and it will be important that
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these data repositories are connected to and interoperable
with traditional institutionally governed initiatives.
The participant-centric model must also integrate the
rights, legal obligations, and interests of other stake-
holders, including researchers, clinicians, and institutions.
To promote cooperation among these various stake-
holders, incentives to share data (or not) must be analyzed
and, where appropriate, augmented (for example, reward-
ing researchers in the areas of promotion, publication
credit, and tenure for sharing data).
4. It is important to reach out to and engage under-
represented populations and to investigate the feasibility
and acceptability of a public health approach
Relying on individuals to voluntarily contribute their
data through existing healthcare delivery and communi-
cation channels will not be enough to engage a truly
diverse group of participants. The situation is further
complicated by the historical mistrust of research based
on past injustices experienced by underserved groups, such
as Native Americans and African Americans, which may
result in under-representation of minority populations in
the MIC. Under-representation will weaken the scientific
generalizability and clinical utility of the resulting resources
by failing to address some of the most genetically diverse
communities, thus missing important scientific insights
and further exacerbating health disparities.
A public health approach featuring automatic enroll-
ment coupled with opt-out mechanisms and robust
protections against data misuse might help ensure a
representative cohort and address concerns about se-
lection bias. Such an approach, however, raises con-
cerns about unjustified and unwanted infringement on
individual liberties. Systematic outreach and alternative
engagement methods and strategies to invite communi-
ties to join the commons are needed to achieve equit-
able representation in the MIC. Some communities
have possible channels for engagement through trusted
intermediaries and community representatives, such as
tribal governments and the Genetic Resource Center of
the National Congress of American Indians, or via
“community engagement studios” [9, 10].
5. Building trust is an iterative process and requires
investment of efforts beyond informed consent
Building trust is essential for a successful MIC. Fostering
and maintaining trust involves active engagement, takes
time, and requires keen tuning to people’s needs, as trust
can easily be damaged and, once lost, it is difficult to
restore. Potential ways to build and sustain trust with par-
ticipants include meaningful and authentic engagement
through trusted intermediaries (including advocacy groups
and foundations) or giving participants a meaningful voice
in governance and/or decisions regarding their data.
Simply relying on traditional requirements for informed
consent is insufficient, especially when obtaining consent
is treated as a transaction rather than an iterative, ongoing
process of communication. Participant choices can change
over time as circumstances change. Such evolution sup-
ports the adoption of dynamic, process-oriented engage-
ment and consent. Other trust-building factors include
transparent communication of data distribution and uses,
clear data-sharing and distribution rules, and meaningful
sanctions for misuse. Demonstration of the financial via-
bility of data repositories would minimize participants’
data security concerns related to disruption of funding or
potential bankruptcy.
6. Regulatory policies that rely on a sharp distinction
between the “kingdom of research” and the “kingdom of
clinical care” must be reconsidered
The current regulatory system clearly distinguishes re-
search data from clinical data. Researchers and clinicians
are governed by different legal rules and ethical norms
when collecting, storing, and using health data, depend-
ing on whether those data were collected as part of a
research study or as part of clinical care. This distinction
is far less meaningful for participants. As long as they
are provided protections against informational harms,
participants are mainly concerned that the data promote
progress toward disease prevention and treatment and
improvements for themselves or others in the future.
The MIC ideally draws on data from both research and
clinical care settings in order to contribute to a learning
healthcare system, as well as incorporating new sources
of “real world” data—such as lifestyle and environmental
exposure data.
Regulatory frameworks governing the MIC should pro-
vide consistent rights and protections to all participants
and data contributors, regardless of the circumstances
leading to their involvement in the MIC, and should ac-
commodate both clinical and scientific uses of shared
data. For example, the Health Insurance Portability and
Accountability Act (HIPAA) Privacy Rule guarantees indi-
viduals a right to access and receive copies of their health
record data, yet this right remains poorly understood, dif-
ficult to exercise, and only covers the portion of a person’s
data held by traditional healthcare providers and other
HIPAA-regulated entities [6, 7]. Accordingly, in the USA,
data exclusively residing in research files (rather than
health records) are not subject to HIPAA’s individual ac-
cess right unless the research laboratory is part of a larger
HIPAA-regulated covered entity [11]. This disparate treat-
ment of research and clinical data may confuse partici-
pants who want to contribute their data to the MIC and
does not make sense in the context of translational gen-
omic research, where sequence data are stored in research
files but have clinical implications.
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7. Changes in technology and in the scale and scope of
data sharing demand reconsideration of current policy
frameworks related to privacy and security
Rich, integrated, multifactorial datasets linking people’s
genomic, clinical, and environmental/lifestyle data are
inherently susceptible to re-identification, even when de-
identified according to current standards. This concern will
only intensify as better infrastructure solutions enable
disparate data and tissue resources and large datasets, in
general, to become linked [12]. In keeping with a commit-
ment to transparency, educating participants and the pub-
lic about the potential for re-identification—without
exaggerating the level of risk or losing sight of the benefits
of data sharing—is important. Few things could destroy
participants’ trust in the MIC more quickly and completely
than unforeseen data breaches and re-identification. While
re-identification risks cannot be eliminated, their likelihood
can be reduced by: (1) requiring more complete account-
ings of disclosures and downstream uses of data in de-
identified forms, (2) developing laws and regulations that
distinguish benign uses of re-identification from nefarious
ones, and (3) implementing stronger sanctions and en-
forcement mechanisms for data misuse [13]. Finally, there
are indications that individuals differ in their degree of
concern about privacy, and in how they view trade-offs
between risk and benefit in the context of data sharing to
facilitate research and improvements in public health
[14, 15]. These differences may justify the use of data-
sharing models that give participants more control over
the level of risk they are willing to incur [15–18].
8. Distinguishing data ownership from data access and
control is critical. Notions of unitary, exclusive property
rights to data run counter to building the MIC
Individuals may believe they alone “own” their healthcare
and related personal data; however, exclusive ownership
that is typically, and often inaccurately, associated with
land and physical objects is especially misplaced in the
context of the MIC, where multiple copies of data exist in
multiple places. The legal status of this information is not
entirely clear. In the USA, courts and legislatures have
rejected individuals’ exclusive ownership claims to both
biospecimens [19–21] and data [6]. Nonetheless, individ-
uals do have recognized rights and interests related to
health and genomic data. For example, individuals have a
right under the HIPAA Privacy Rule to access and retain
copies of their health data. However, since they do not ex-
clusively own those data, they cannot prevent care delivery
institutions from retaining copies of the data as they
are legally obligated to do so in order to have a proper
record of each patient’s care. In addition, the concept
of exclusive ownership is in direct tension with the
notion of a commons and is antithetical to the goals
of the MIC. Governance structures in the MIC should
focus on these non-mutually exclusive rights and interests,
as well as legal and moral concepts such as trusted, custo-
dial, and fiduciary relationships.
Conclusions
Progress in biomedical research and movement toward a
learning health system that can fully take advantage of
precision medicine will depend on building a robust MIC.
The challenges are many and substantial. We propose
eight principles that, if built into data-sharing infrastruc-
ture and practices, can improve prospects for developing a
trusted MIC. While there is a moral obligation to use the
data and a duty toward the people who are contributing
the data, the moral imperative alone is insufficient to
make data sharing successful and sustainable. There must
be standard approaches to policy and governance of data
initiatives in the MIC ecosystem (principle 1) that bring
together data from diverse individuals (principle 2). It is
essential that participants reside at the center of the MIC
(principle 3), under-represented populations are engaged
(principle 4), and there is investment in efforts beyond
informed consent to build and sustain trust (principle 5).
Finally, legal, regulatory, and technical barriers and
enablers for data sharing must also be considered and
updated (principles 6–8).
These eight core principles provide a framework for ad-
vancing the policy response to data-sharing opportunities
and challenges. If these principles are followed, the result-
ing MIC can promote broader data use (for both clinical
applications and the advancement of research interests),
be more inclusive and result in more diverse participation,
and accrue more benefits and avoid informational
harms to participants. Adoption of these principles by
stakeholders will increase the likelihood that the MIC
ecosystem will fulfill the promise of precision medicine.
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